Nation sees therapeutics success
admin
2023-01-28 12:13:16
0

Pharmacists check prescription information at a fever clinic in Minhang district of Shanghai on Jan 8. The small molecule drugs to treat COVID-19 had been put into use in community health centers in Shanghai to better play their roles in "early detection, early intervention and early diversion". WANG XIANG/XINHUA

Domestically developed COVID-19 drug therapies lower risk of hospitalization

China will create broad-spectrum treatments to tackle mutated strains of the COVID-19 virus and develop drugs with novel mechanisms to fight the pathogen, according to a document provided to China Daily.

As of Jan 19, a total of 10 domestically made COVID-19 drugs had either been granted official or conditional market approval or were authorized to treat symptoms of the pathogen, the document stated.

The document was issued by the specialized team for COVID-19 medicine research and development under the Joint Prevention and Control Mechanism of the State Council, China's Cabinet.

China also had 23 drugs on the key COVID-19 medicine list that were in active development or undergoing real-world evidence studies after receiving market approval, it said.

"The team will continue to facilitate the development of safe and effective treatments that can cover the whole course of the disease and are suitable for all populations," it added.

Since the COVID-19 pandemic began, China's novel coronavirus drug development process has followed three broad technical paths- stopping the virus from entering cells, inhibiting viral replication in the body and regulating the body's immune system.

In December 2021, China granted official market approval to its first homegrown neutralizing monoclonal neutralizing antibody cocktails - BRII-196 and BRII-198. It is a combination therapy administered through intravenous infusion that can lower the risk of hospitalization and death by nearly 80 percent, according to its phase-three clinical trial results.

Meanwhile, Chinese scientists have been developing small-molecule oral treatments for COVID-19.A breakthrough came in July when China granted conditional authorization for the oral antiviral Azvudine to treat COVID-19. The drug was originally used to treat HIV.

This year, China will accelerate the development of small-molecule oral drugs. In mid-January, the National Medical Products Administration received applications for market approval for new antivirals SIM0417 and VV116. Another antiviral called RAY1216 had recently finished recruiting for its late-stage clinical trials.

Besides finding treatments for COVID-19, Chinese scientists are researching new drugs to prevent infections or regulate the body's immune system, with a handful of candidates currently in phase two or three clinical trials. Some notable examples include the targeted inhibitor drug TDI01 and HY3000 peptide nasal spray.

zhangzhihao@chinadaily.com.cn

相关内容

热门资讯

股价走高触发强赎 7月将有两只... 近日,银行正股股价表现强势,多只银行转债触发强制赎回条款。7月1日是杭银转债最后一个交易日,其最后转...
300548,“改名”,股价历... 科技股和顺周期板块再现“跷跷板”走势。今天上午,顺周期板块走强,银行、有色金属、白酒、新能源等板块上...
明阳电路在昆山投资成立集成电路... 人民财讯7月2日电,企查查APP显示,近日,昆山华芯微测集成电路有限公司成立,法定代表人为窦旭才,经...
民生银行“易创E贷”获“202... 在近日举行的第七届数字普惠金融大会上,民生银行“易创E贷”产品凭借在服务科技型中小微企业的创新与实践...
机器人大军逼近,很快,亚马逊的...   炒股就看金麒麟分析师研报,权威,专业,及时,全面,助您挖掘潜力主题机会! 亚马逊正迅速接近仓库...
广东省教育考试院通报:不存在中... 7月2日,广东省教育考试院发布通报称,7月1日下午广东省初中学业水平考试(以下简称“中考”)数学科目...
国际油价承压 中东油企拟放缓全... 财联社7月2日讯(编辑 秦嘉禾)在国际油价下行压力加剧背景下,中东两大国有能源巨头——沙特阿美(Sa...
光伏50ETF、光伏龙头ETF... 光伏设备板块走强,亿晶光电、欧晶科技涨停。银华光伏50ETF、汇添富光伏龙头ETF、浦银安盛光伏龙头...
世界银行发布重磅预测:黄金今年... 错过上半年,别再错过下半年!世界银行继续看好贵金属前景,黄金、白银、铂金或将继续延续强势……世界银行...
洪灝称高分红投资策略应继续有所... 【#洪灝称高分红投资策略应继续有所表现#】中国股市近期一个显著趋势是分红和回购活动显著增加。其中,许...